# Peptides Studied for Alzheimer’s Disease: The Trials

Source: https://pepvault.app/conditions/alzheimers-disease

Last updated: 2026-11-19

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [By condition](https://pepvault.app/conditions) Alzheimer’s Disease

Peptides by condition · Brain and nerves

# Peptides studied for Alzheimer’s disease and dementia

Checked November 2026 against our study pages and the FDA labels [Published by PepVault](https://pepvault.app/guides/how-we-research)

Our library holds 9 study pages on Alzheimer’s disease and dementia: 2 in people (all meta-analyses or randomized trials), and 6 in animals and 1 in cells. They studied 6 compounds, with this many study pages each: Semaglutide (oral) 1, Cerebrolysin 1, P21 3, Dihexa 2, Vesugen 1 and Thymosin Beta-4 1.

## What the research on Alzheimer’s disease and dementia looks like

Read the design before any result. Of these 9 studies, 1 was done on cells in a dish, 6 were in animals and 2 were in people, the largest with 3,808 people. A finding in cells or animals is where research starts, and many such findings do not hold up in people.

Alzheimer’s disease slowly destroys memory and thinking, and no medicine yet stops it. Most of the peptide research on it was done in rodents, in mice bred to build up the proteins amyloid and tau or in old rats, and in brain tissue grown in a dish. Only a small share was tested in people with the disease.

Trials in people score memory and thinking on standard tests and a clinician’s rating of overall change over months. Animal studies use maze tests and measure amyloid, tau and the connections between nerve cells.

Results in Alzheimer’s mice have a long record of not carrying over to people, so the design of each study matters more than its headline. The largest trials in people are the strongest test.

How many of the 9 study pages on this condition reach each design, strongest at the top: meta-analyses and randomized trials in people, other studies in people, animals, cells.

## The 9 studies, by compound

Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.

1. ### [Semaglutide (oral)](https://pepvault.app/peptides/semaglutide-oral)

   1 in people

   For Alzheimer’s disease and dementia, 1 of our study pages is filed under Semaglutide (oral): 1 randomized trial in people. It enrolled 3,808 people and was published in 2026, in Lancet.

   FDA-approved for other uses, not for Alzheimer’s disease and dementia: Rybelsus (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk; Wegovy (tablet) for weight loss and keeping it off, and lowering heart risk in adults with heart disease and excess weight; Ozempic (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk (the same label as Rybelsus).

   - Randomized trial in people · 3,808 people · 2026 [Semaglutide (oral) did not slow early Alzheimer's in evoke trials](https://pepvault.app/research/semaglutide-oral-evoke-and-evoke-2026)

   - [Semaglutide (oral): legal and regulatory status](https://pepvault.app/peptides/semaglutide-oral/legal-status)
   - [Semaglutide (oral) in the library](https://pepvault.app/peptides/semaglutide-oral)
   - [Semaglutide (oral) dose guide](https://pepvault.app/lab/dosage/semaglutide-oral)
2. ### [Cerebrolysin](https://pepvault.app/peptides/cerebrolysin)

   1 in people

   For Alzheimer’s disease and dementia, 1 of our study pages is filed under Cerebrolysin: 1 meta-analysis in people. It was published in 2015, in Dement Geriatr Cogn Disord, and our page does not give its size.

   Cerebrolysin has no FDA-approved product: Drugs@FDA lists no application for it.

   - Meta-analysis in people · 2015 [Cerebrolysin beat placebo on global change in Alzheimer's at 6 months](https://pepvault.app/research/cerebrolysin-gauthier-2015)

   - [Cerebrolysin: legal and regulatory status](https://pepvault.app/peptides/cerebrolysin/legal-status)
   - [Cerebrolysin in the library](https://pepvault.app/peptides/cerebrolysin)
   - [Cerebrolysin dose guide](https://pepvault.app/lab/dosage/cerebrolysin)
3. ### [P21](https://pepvault.app/peptides/p21)

   3 in animals

   For Alzheimer’s disease and dementia, 3 of our study pages are filed under P21: 3 animal studies (mice and rats). None of them is in people. They were published from 2014 to 2020, in Alzheimers Res Ther, J Alzheimers Dis and Neurobiol Dis.

   P21 has no FDA-approved product: Drugs@FDA lists no application for it.

   - Animal study in mice · 2020 [P21 in early life rescued Alzheimer-like deficits in mice](https://pepvault.app/research/p21-wei-2020)
   - Animal study in rats · 2015 [P21: lowered tau in the brain and spinal fluid of aged rats](https://pepvault.app/research/p21-khatoon-2015)
   - Animal study in mice · 2014 [P21 reduced tau buildup and cognitive deficits in Alzheimer's mice](https://pepvault.app/research/p21-kazim-2014)

   - [P21: legal and regulatory status](https://pepvault.app/peptides/p21/legal-status)
   - [P21 in the library](https://pepvault.app/peptides/p21)
   - [P21 dose guide](https://pepvault.app/lab/dosage/p21)
4. ### [Dihexa](https://pepvault.app/peptides/dihexa)

   2 in animals

   For Alzheimer’s disease and dementia, 2 of our study pages are filed under Dihexa: 2 animal studies (mice and rats). None of them is in people. They were published from 2013 to 2021, in Brain Sci and J Pharmacol Exp Ther.

   Dihexa has no FDA-approved product: Drugs@FDA lists no application for it.

   - Animal study in mice · 2021 [Dihexa restored spatial learning and memory in APP/PS1 mice](https://pepvault.app/research/dihexa-sun-2021)
   - Animal study in rats · 2013 [Dihexa showed antidementia activity in scopolamine and aged rat models](https://pepvault.app/research/dihexa-mccoy-2013)

   - [Dihexa: legal and regulatory status](https://pepvault.app/peptides/dihexa/legal-status)
   - [Dihexa in the library](https://pepvault.app/peptides/dihexa)
   - [Dihexa dose guide](https://pepvault.app/lab/dosage/dihexa)
5. ### [Vesugen](https://pepvault.app/peptides/vesugen)

   1 in animals

   For Alzheimer’s disease and dementia, 1 of our study pages is filed under Vesugen: 1 animal study (mice). It was published in 2021, in Pharmaceuticals (Basel).

   Vesugen has no FDA-approved product: Drugs@FDA lists no application for it.

   - Animal study in mice · 2021 [Vesugen (KED) prevented dendritic spine loss in Alzheimer's mice](https://pepvault.app/research/vesugen-khavinson-2021)

   - [Vesugen: legal and regulatory status](https://pepvault.app/peptides/vesugen/legal-status)
   - [Vesugen in the library](https://pepvault.app/peptides/vesugen)
   - [Vesugen dose guide](https://pepvault.app/lab/dosage/vesugen)
6. ### [Thymosin Beta-4](https://pepvault.app/peptides/thymosin-beta-4)

   1 in cells

   For Alzheimer’s disease and dementia, 1 of our study pages is filed under Thymosin Beta-4: 1 cell study (human brain organoids). It was published in 2025, in Stem Cell Reports.

   Thymosin beta-4 has no FDA-approved product: Drugs@FDA lists no application for it.

   - Cell study in human brain organoids · 2025 [Thymosin beta-4 rescued AD-linked defects in human brain organoids](https://pepvault.app/research/thymosin-beta-4-zeng-2025)

   - [Thymosin Beta-4: legal and regulatory status](https://pepvault.app/peptides/thymosin-beta-4/legal-status)
   - [Thymosin Beta-4 in the library](https://pepvault.app/peptides/thymosin-beta-4)
   - [Thymosin Beta-4 dose guide](https://pepvault.app/lab/dosage/thymosin-beta-4)

## On Alzheimer’s disease and dementia

### Semaglutide (oral)

- [Semaglutide (oral): the full reference](https://pepvault.app/peptides/semaglutide-oral)
- [Semaglutide (oral) dose guide](https://pepvault.app/lab/dosage/semaglutide-oral)

### Cerebrolysin

- [Cerebrolysin: the full reference](https://pepvault.app/peptides/cerebrolysin)
- [Cerebrolysin dose guide](https://pepvault.app/lab/dosage/cerebrolysin)

### Studies

- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [Semaglutide (oral) did not slow early Alzheimer's in evoke trials](https://pepvault.app/research/semaglutide-oral-evoke-and-evoke-2026)
- [Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4](https://pepvault.app/research/semaglutide-oasis-4-2025)
- [All 6 studies](https://pepvault.app/research#semaglutide-oral)
- [Cerebrolysin: small cognitive gain in vascular dementia, weak evidence](https://pepvault.app/research/cerebrolysin-cui-2019)
- [Cerebrolysin: better NIHSS scores after stroke across nine trials](https://pepvault.app/research/cerebrolysin-bornstein-2018)
- [Cerebrolysin beat placebo on global change in Alzheimer's at 6 months](https://pepvault.app/research/cerebrolysin-gauthier-2015)
- [All 6 studies](https://pepvault.app/research#cerebrolysin)

### Compared with

- [Semaglutide vs Semaglutide (oral)](https://pepvault.app/peptides/compare/semaglutide-vs-semaglutide-oral)
- [Orforglipron vs Semaglutide (oral)](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide-oral)
- [Semax vs Cerebrolysin](https://pepvault.app/peptides/compare/semax-vs-cerebrolysin)
- [Semax vs Dihexa](https://pepvault.app/peptides/compare/semax-vs-dihexa)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Related conditions

- [Peptides studied for heart disease](https://pepvault.app/conditions/heart-disease)
- [Peptides studied for type 2 diabetes](https://pepvault.app/conditions/type-2-diabetes)
- [Peptides studied for stroke](https://pepvault.app/conditions/stroke)
- [Peptides studied for nerve damage (neuropathy)](https://pepvault.app/conditions/neuropathy)

### By goal

- [Peptides for focus and memory](https://pepvault.app/peptides/for/focus-and-memory)
- [Peptides for injury recovery and healing](https://pepvault.app/peptides/for/injury-recovery)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)

## Side by side

For the 6 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).

| Compound | In people | Animals or cells | Largest in people | FDA |
| --- | --- | --- | --- | --- |
| [Semaglutide (oral)](https://pepvault.app/peptides/semaglutide-oral) | 1 | 0 | 3,808 | Approved for other uses |
| [Cerebrolysin](https://pepvault.app/peptides/cerebrolysin) | 1 | 0 | — | Not approved |
| [P21](https://pepvault.app/peptides/p21) | 0 | 3 | — | Not approved |
| [Dihexa](https://pepvault.app/peptides/dihexa) | 0 | 2 | — | Not approved |
| [Vesugen](https://pepvault.app/peptides/vesugen) | 0 | 1 | — | Not approved |
| [Thymosin Beta-4](https://pepvault.app/peptides/thymosin-beta-4) | 0 | 1 | — | Not approved |

## What the studies did not show

Each study page names its own limits. These are the questions still open, in the study pages’ words.

- [Semaglutide (oral) did not slow early Alzheimer's in evoke trials](https://pepvault.app/research/semaglutide-oral-evoke-and-evoke-2026) The trials tested only the 14 mg flexible dose of the oral form, in people with early, amyloid-confirmed Alzheimer's, and only 54 (2.8%) people in evoke+ had small vessel pathology. Both trials were stopped because of the negative result, and they were funded by Novo Nordisk.
- [Cerebrolysin beat placebo on global change in Alzheimer's at 6 months](https://pepvault.app/research/cerebrolysin-gauthier-2015) The pooled results cover two time points, 4 weeks and 6 months, and mix individual patient data with published group results across 6 trials. The cognitive benefit seen at 4 weeks was not statistically significant at 6 months.
- [P21: lowered tau in the brain and spinal fluid of aged rats](https://pepvault.app/research/p21-khatoon-2015) This was done in rats, so it does not show the same effect in people. The study measured tau and amyloid markers, not memory or other signs of dementia, and it did not test people with Alzheimer's disease.
- [Dihexa restored spatial learning and memory in APP/PS1 mice](https://pepvault.app/research/dihexa-sun-2021) This is mouse work in one Alzheimer's research strain, so it does not show that Dihexa does the same in people. No humans were studied.
- [Vesugen (KED) prevented dendritic spine loss in Alzheimer's mice](https://pepvault.app/research/vesugen-khavinson-2021) This was work in mice and in computer models, not a result in people, and the neuroplasticity effect was only a trend. The gene binding sites were predicted by modeling for EDR, not measured for KED.

This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.

## Related pages

- [Peptides studied for heart disease 2 compounds in common](https://pepvault.app/conditions/heart-disease)
- [Peptides studied for type 2 diabetes 1 compound in common](https://pepvault.app/conditions/type-2-diabetes)
- [Peptides studied for stroke 1 compound in common](https://pepvault.app/conditions/stroke)
- [Peptides studied for nerve damage (neuropathy) 1 compound in common](https://pepvault.app/conditions/neuropathy)

### By goal

- [Peptides for focus and memory](https://pepvault.app/peptides/for/focus-and-memory)
- [Peptides for injury recovery and healing](https://pepvault.app/peptides/for/injury-recovery)

### Trial terms

- [Randomized controlled trial (RCT)](https://pepvault.app/glossary/randomized-controlled-trial)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Phase 1, 2 and 3 trials](https://pepvault.app/glossary/clinical-trial-phases)
- [Meta-analysis](https://pepvault.app/glossary/meta-analysis)
- [In vivo](https://pepvault.app/glossary/in-vivo)
- [In vitro](https://pepvault.app/glossary/in-vitro)

## Questions

### Which peptides have been studied for Alzheimer’s disease and dementia?

Our 9 study pages on Alzheimer’s disease and dementia are filed under 6 compounds, with this many each: Semaglutide (oral) 1, Cerebrolysin 1, P21 3, Dihexa 2, Vesugen 1 and Thymosin Beta-4 1. P21 has the most.

### Have any been tested in people with Alzheimer’s disease and dementia?

Yes: 2 of the 9 were in people, all of them meta-analyses or randomized trials (Semaglutide (oral) and Cerebrolysin). The largest enrolled 3,808 people: “Semaglutide (oral) did not slow early Alzheimer's in evoke trials” (2026).

### Is any peptide FDA-approved for Alzheimer’s disease and dementia?

Not by the labels our status pages read: of the 6 compounds here with an FDA record, none has a use tied to Alzheimer’s disease and dementia. Semaglutide (oral) is FDA-approved for other uses.

### How large were the studies in people on Alzheimer’s disease and dementia?

Of the 2 in people, 1 gives its size on our pages: 1 had 1,000 people or more. The largest, a randomized trial from 2026, enrolled 3,808.

### What did the animal and cell studies on Alzheimer’s disease and dementia use?

6 animal studies (mice and rats) and 1 cell study (human brain organoids), filed under Dihexa, Vesugen, P21 and Thymosin Beta-4. A result in animals or cells shows what to test next, not what happens in a person.

### What is the newest study on Alzheimer’s disease and dementia here?

Of our study pages on Alzheimer’s disease and dementia, the newest is “Semaglutide (oral) did not slow early Alzheimer's in evoke trials”, a randomized trial in people published in 2026.

## How this page was built

A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.

Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.

## On Alzheimer’s disease and dementia

### Semaglutide (oral)

- [Semaglutide (oral): the full reference](https://pepvault.app/peptides/semaglutide-oral)
- [Semaglutide (oral) dose guide](https://pepvault.app/lab/dosage/semaglutide-oral)

### Cerebrolysin

- [Cerebrolysin: the full reference](https://pepvault.app/peptides/cerebrolysin)
- [Cerebrolysin dose guide](https://pepvault.app/lab/dosage/cerebrolysin)

### Studies

- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [Semaglutide (oral) did not slow early Alzheimer's in evoke trials](https://pepvault.app/research/semaglutide-oral-evoke-and-evoke-2026)
- [Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4](https://pepvault.app/research/semaglutide-oasis-4-2025)
- [All 6 studies](https://pepvault.app/research#semaglutide-oral)
- [Cerebrolysin: small cognitive gain in vascular dementia, weak evidence](https://pepvault.app/research/cerebrolysin-cui-2019)
- [Cerebrolysin: better NIHSS scores after stroke across nine trials](https://pepvault.app/research/cerebrolysin-bornstein-2018)
- [Cerebrolysin beat placebo on global change in Alzheimer's at 6 months](https://pepvault.app/research/cerebrolysin-gauthier-2015)
- [All 6 studies](https://pepvault.app/research#cerebrolysin)

### Compared with

- [Semaglutide vs Semaglutide (oral)](https://pepvault.app/peptides/compare/semaglutide-vs-semaglutide-oral)
- [Orforglipron vs Semaglutide (oral)](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide-oral)
- [Semax vs Cerebrolysin](https://pepvault.app/peptides/compare/semax-vs-cerebrolysin)
- [Semax vs Dihexa](https://pepvault.app/peptides/compare/semax-vs-dihexa)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Related conditions

- [Peptides studied for heart disease](https://pepvault.app/conditions/heart-disease)
- [Peptides studied for type 2 diabetes](https://pepvault.app/conditions/type-2-diabetes)
- [Peptides studied for stroke](https://pepvault.app/conditions/stroke)
- [Peptides studied for nerve damage (neuropathy)](https://pepvault.app/conditions/neuropathy)

### By goal

- [Peptides for focus and memory](https://pepvault.app/peptides/for/focus-and-memory)
- [Peptides for injury recovery and healing](https://pepvault.app/peptides/for/injury-recovery)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)

## By condition

- [Every condition](https://pepvault.app/conditions)
- [Peptides studied for heart disease](https://pepvault.app/conditions/heart-disease)
- [Peptides studied for type 2 diabetes](https://pepvault.app/conditions/type-2-diabetes)
- [Peptides studied for stroke](https://pepvault.app/conditions/stroke)
- [Peptides studied for nerve damage (neuropathy)](https://pepvault.app/conditions/neuropathy)

## The research

- [Studies, in plain English](https://pepvault.app/research)
- [The peptide reference library](https://pepvault.app/peptides)
- [Peptides by goal](https://pepvault.app/peptides/for)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
